1. Home
  2. PNR vs IONS Comparison

PNR vs IONS Comparison

Compare PNR & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pentair plc.

PNR

Pentair plc.

HOLD

Current Price

$89.53

Market Cap

13.6B

Sector

Industrials

ML Signal

HOLD

Logo Ionis Pharmaceuticals Inc.

IONS

Ionis Pharmaceuticals Inc.

HOLD

Current Price

$74.87

Market Cap

11.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PNR
IONS
Founded
1966
1989
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.6B
11.9B
IPO Year
2003
1996

Fundamental Metrics

Financial Performance
Metric
PNR
IONS
Price
$89.53
$74.87
Analyst Decision
Buy
Strong Buy
Analyst Count
15
22
Target Price
$113.36
$92.73
AVG Volume (30 Days)
1.2M
1.6M
Earning Date
04-28-2026
04-29-2026
Dividend Yield
1.20%
N/A
EPS Growth
5.88
21.71
EPS
3.96
N/A
Revenue
N/A
N/A
Revenue This Year
$4.24
N/A
Revenue Next Year
$4.82
$77.99
P/E Ratio
$22.77
N/A
Revenue Growth
N/A
N/A
52 Week Low
$83.60
$28.79
52 Week High
$113.95
$86.74

Technical Indicators

Market Signals
Indicator
PNR
IONS
Relative Strength Index (RSI) 48.61 48.81
Support Level $87.98 $69.85
Resistance Level $91.13 $77.08
Average True Range (ATR) 1.98 1.99
MACD 0.52 0.18
Stochastic Oscillator 66.99 49.24

Price Performance

Historical Comparison
PNR
IONS

About PNR Pentair plc.

Pentair is a global leader in the water treatment industry, with 10,000 employees and a presence in 25 countries. Its business is organized into three segments: pool, water technologies, and flow. The company offers a wide range of water solutions, including energy-efficient swimming pool equipment, filtration solutions, and commercial and industrial pumps. Pentair generated approximately $4.2 billion in revenue in 2025.

About IONS Ionis Pharmaceuticals Inc.

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).

Share on Social Networks: